Prospective Randomized Open-label Trial Protocol Investigating the Addition of Pegylated Interferon-alpha to an Ongoing Nucleos(t)ide Treatment Regimen of HBeAg Negative Chronic Hepatitis B Patients (PADD-ON)

Open Label Trial ◽

LP29 : A randomised prospective open-label trial comparing peginterferon + adefovir and peginterferon + tenofovir versus no treatment in hbeag negative chronic hepatitis b patients with low viral load: analysis of week 48 results

10.1016/s0168-8278(15)30183-5 ◽

2015 ◽

Vol 62 ◽

pp. S278-S279

Author(s):

A. de Niet ◽

L. Jansen ◽

F. Stelma ◽

S.B. Willemse ◽

S.D. Kuiken ◽

...

Keyword(s):

Chronic Hepatitis ◽

Viral Load ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Open Label ◽

Open Label Trial ◽

Load Analysis ◽

Combination Therapy of Pegylated Interferon alpha 2b (PegIFN) and Adefovir Dipivoxil (ADV) in Chronic Hepatitis B (CH-B) Patients Reduces the Reservoir of Transcriptionally Active cccDNA and Hepatitis B Surface Antigen (HBsAg)

Zeitschrift für Gastroenterologie ◽

10.1055/s-2005-862299 ◽

2005 ◽

Vol 43 (01) ◽

Author(s):

F Metzler ◽

K Wursthorn ◽

B Zoellner ◽

P Buggisch ◽

M Zankel ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Combination Therapy ◽

Chronic Hepatitis B ◽

Interferon Alpha ◽

Adefovir Dipivoxil ◽

Hepatitis B Surface Antigen ◽

Pegylated Interferon ◽

Interferon Alpha 2B

Efficacy and safety of interferon alpha-2b versus pegylated interferon alpha-2a monotherapy in children with chronic hepatitis B: a real-life cohort study from Shanghai, China

World Journal of Pediatrics ◽

10.1007/s12519-019-00303-w ◽

2019 ◽

Vol 15 (6) ◽

pp. 595-600 ◽

Cited By ~ 3

Author(s):

Yao Hu ◽

Ying-Zi Ye ◽

Li-Jing Ye ◽

Xiao-Hong Wang ◽

Hui Yu

Keyword(s):

Chronic Hepatitis ◽

Cohort Study ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Interferon Alpha ◽

Real Life ◽

Pegylated Interferon ◽

Efficacy And Safety ◽

Interferon Alpha 2B

Effect of pegylated interferon alfa-2a in HBeAg-negative chronic hepatitis B during and 48 weeks after off-treatment follow-up: the limitation of pre-treatment HBsAg load for the seroclearance of HBsAg

Internal and Emergency Medicine ◽

10.1007/s11739-020-02622-7 ◽

2021 ◽

Author(s):

Shima Mimura ◽

Koji Fujita ◽

Kei Takuma ◽

Mai Nakahara ◽

Kyoko Oura ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Pegylated Interferon Alfa ◽

Pre Treatment ◽

Sa1313 Sequential Nuc Therapy Following Pegylated Interferon-Alpha Exposure Restores Innate Immune Responses Conferring a Treatment Advantage Over Nuc Monotherapy in Chronic Hepatitis B

Gastroenterology ◽

10.1016/s0016-5085(14)60915-x ◽

2014 ◽

Vol 146 (5) ◽

pp. S-260

Author(s):

Upkar S. Gill ◽

Dimitra Peppa ◽

Lorenzo Micco ◽

Harsimran D. Singh ◽

Graham Foster ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Immune Responses ◽

Chronic Hepatitis B ◽

Interferon Alpha ◽

Pegylated Interferon ◽

Innate Immune ◽

Innate Immune Responses ◽

Pegylated Interferon Alpha

Assessment of Quality of Life of Patients with Chronic Hepatitis B and C Treated with Pegylated Interferon-alpha

Viral Hepatitis Journal ◽

10.4274/vhd.2017.0016 ◽

2018 ◽

Vol 24 (2) ◽

pp. 25-42

Author(s):

Handan ALAY ◽

Kemalettin ÖZDEN ◽

Serpil EROL ◽

Neslihan ÇELİK ◽

Emine PARLAK ◽

...

Keyword(s):

Quality Of Life ◽

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Interferon Alpha ◽

Pegylated Interferon ◽

Pegylated Interferon Alpha

Kinetics of serum HBsAg and HBcrAg in predicting response to pegylated interferon-based therapy in patients with HBeAg-negative chronic hepatitis B

10.1016/s0168-8278(17)31854-8 ◽

2017 ◽

Vol 66 (1) ◽

pp. S690

Author(s):

N. Chuaypen ◽

S. Chittmittraprap ◽

N. Hirankarn ◽

S. Treeprasertsuk ◽

Y. Tanaka ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Pegylated Interferon ◽

Serum Hbsag ◽

Kinetics Of ◽

Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis B virus DNA: a randomised, controlled, open-label trial

The Lancet Gastroenterology & Hepatology ◽

10.1016/s2468-1253(16)30189-3 ◽

2017 ◽

Vol 2 (3) ◽

pp. 177-188 ◽

Cited By ~ 42

Author(s):

Marc Bourlière ◽

Pascaline Rabiega ◽

Nathalie Ganne-Carrie ◽

Lawrence Serfaty ◽

Patrick Marcellin ◽

...

Keyword(s):

Hepatitis B ◽

Pegylated Interferon ◽

Open Label ◽

Undetectable Plasma ◽

Hbe Antigen ◽

B Virus ◽

Pegylated Interferon Alfa ◽

Open Label Trial ◽

Randomised Controlled ◽

51 Early hepatitis B viral dynamics and end of treatment virological response (ETVR) in chronic hepatitis B/ HBeAg (−) patients receiving 1528 0689V 2 pegylated interferon alpha-2b and/or lamivudine

10.1016/s0168-8278(06)80516-7 ◽

2006 ◽

Vol 44 ◽

pp. S192

Author(s):

T. Vassiliadis ◽

V. Sypsa ◽

K. Mimidis ◽

N.C. Tassopoulos ◽

D. Chrysagis ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Chronic Hepatitis B ◽

Interferon Alpha ◽

Virological Response ◽

Pegylated Interferon ◽

Viral Dynamics ◽

Interferon Alpha 2B ◽

End Of Treatment

499 FULL GENOME ULTRA-DEEP PYROSEQUENCING IDENTIFIES GG-TO-GA HYPERMUTATION AS NOVEL PREDICTOR FOR TREATMENT RESPONSE TO PEGYLATED INTERFERON ALFA-2A IN HBEAG-NEGATIVE CHRONIC HEPATITIS B

10.1016/s0168-8278(12)60512-1 ◽

2012 ◽

Vol 56 ◽

pp. S197

Author(s):

B. Beggel ◽

C. Münk ◽

M. Däumer ◽

K. Hauck ◽

G. Lawyer ◽

...

Keyword(s):

Chronic Hepatitis ◽

Hepatitis B ◽

Treatment Response ◽

Chronic Hepatitis B ◽

Pegylated Interferon ◽

Interferon Alfa ◽

Full Genome ◽

Pegylated Interferon Alfa ◽